Literature DB >> 31403857

Immunotherapy in Ovarian Cancer: Are We There Yet?

Lana E Kandalaft1, Kunle Odunsi2, George Coukos1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31403857     DOI： 10.1200/JCO.19.00508

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  30 in total

1.  Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer.

Authors:  Hui Li; Miaofang Wu; Zhuna Wu; Jinxiao Liang; Lijuan Wang; Xi Yang; Zhongqiu Lin; Jing Li
Journal:  Cancer Immunol Immunother       Date:  2021-11-01       Impact factor: 6.968

2.  Robust prognostic model based on immune infiltration-related genes and clinical information in ovarian cancer.

Authors:  Xi Zhang; Weikaixin Kong; Miaomiao Gao; Weiran Huang; Chao Peng; Zhuo Huang; Zhengwei Xie; Hongyan Guo
Journal:  J Cell Mol Med       Date:  2022-06-23       Impact factor: 5.295

3.  Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer.

Authors:  Fangran Liu; Jiao Liu; Jinguo Zhang; Jimin Shi; Lu Gui; Guoxiong Xu
Journal:  Cancer Biol Ther       Date:  2020-10-12       Impact factor: 4.742

Review 4.  PARP inhibitors and immunotherapy in ovarian and endometrial cancers.

Authors:  Rowan E Miller; Amy J Lewis; Melanie E Powell
Journal:  Br J Radiol       Date:  2021-06-09       Impact factor: 3.039

5.  Therapy resistance on the RADar in ovarian cancer.

Authors:  Jonas Schwickert; Franziska M Zickgraf; Martin R Sprick
Journal:  EMBO Mol Med       Date:  2021-03-29       Impact factor: 12.137

6.  Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer.

Authors:  Rebecca L Porter; Ursula A Matulonis
Journal:  J Clin Oncol       Date:  2021-09-16       Impact factor: 44.544

Review 7.  Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches.

Authors:  Innocenza Palaia; Federica Tomao; Carolina Maria Sassu; Lucia Musacchio; Pierluigi Benedetti Panici
Journal:  Onco Targets Ther       Date:  2020-06-26       Impact factor: 4.147

8.  Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis.

Authors:  Jiacheng Shen; Tingwei Liu; Qiaoli Bei; Shaohua Xu
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

9.  RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers.

Authors:  Wendell D Jones; Chad M Michener; Charles Biscotti; Iona Braicu; Jalid Sehouli; Mahrukh K Ganapathi; Ram N Ganapathi
Journal:  Cancers (Basel)       Date:  2020-03-07       Impact factor: 6.639

10.  LPS and IL-8 activated umbilical cord blood-derived neutrophils inhibit the progression of ovarian cancer.

Authors:  Qi Liu; Weihong Yang; Ning Luo; Jie Liu; Yuliang Wu; Jinye Ding; Caixia Li; Zhongping Cheng
Journal:  J Cancer       Date:  2020-05-18       Impact factor: 4.207
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.